Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.

摘要: Heart failure is the most common malignant disease in developed world. Levosimendan (Simdax®) a novel intravenous agent that exerts inotropic effects through sensitization of myofilaments to calcium and vasodilator by opening ATP-dependent potassium channels on vascular smooth muscle. Infusion levosimendan increases cardiac output due an increase stroke volume heart rate, with fall pulmonary capillary wedge pressure. It has active metabolite half-life about 80 h, therefore infusions 6 24 h result hemodynamic persist for 7 10 days. Preliminary observations suggest single infusion lasting patients severe left ventricular systolic dysfunction results changes, symptomatic benefit reduction morbidity mortality over following 2 4 weeks compared placebo one study dobutamine another. Long-term follow-up suggests no loss this ...